Recce Pharmaceuticals Ltd

RCE

AU000000RCE5

Pharmaceuticals

Market Closed - Australian S.E. Other stock markets 06:58:22 17/07/2024 BST			5-day change	1st Jan Change
0.46 ^AUD	-2.13%		-1.08%	-14.02%

07-15	Recce Pharmaceuticals Secures $2 Million US Defense Funding for Topical Medication	MT
07-10	Recce Pharmaceuticals Announces Positive Preclinical Efficacy Data Against WHO Priority Pathogen Acinetobacter Baumannii	CI

8,754,423 Class A Performance Shares of Recce Limited are subject to a Lock-Up Agreement Ending on 15-JAN-2018.

January 14, 2018

8,754,423 Class A Performance Shares of Recce Limited are subject to a Lock-Up Agreement Ending on 15-JAN-2018. These shares will be under lockup for 733 days starting from 13-JAN-2016 to 15-JAN-2018.

Latest news about Recce Pharmaceuticals Ltd

Recce Pharmaceuticals Secures $2 Million US Defense Funding for Topical Medication	07-15	MT
Recce Pharmaceuticals Announces Positive Preclinical Efficacy Data Against WHO Priority Pathogen Acinetobacter Baumannii	07-10	CI
Recce Pharmaceuticals' Anti-Infective Drug Candidate Showed Activity Against 'Superbug' in Skin Cell Study	07-08	MT
Recce Pharmaceuticals Reports Positive Data from Phase I/Ii Urinary Tract Infection / Urosepsis Rapid Infusion Trial of Recce® 327	07-01	CI
Recce Pharmaceuticals' Phase 1/2 Urinary Tract Infection Trial Meets Primary Endpoints; Shares Up 4%	06-28	MT
Recce Pharmaceuticals Ltd. Receives Ethics Approval to Broaden RECCE 327 Gel Trials Across All Topical Bacterial Skin Infections	06-25	CI
Recce Pharmaceuticals Secures Ethics Approval for Bacterial Skin Infection Study	06-24	MT
Recce Pharmaceuticals Announces Addition of RECCE® 327 to the World Health Organization?S List of Antibacterial Products in Clinical Development	06-20	CI
Recce Pharmaceuticals' RECCE 327 Added to WHO's List of Antibacterial Products in Clinical Development	06-18	MT
Recce Pharmaceuticals Completes Dosing in Urosepsis Rapid Infusion Clinical Trial	06-11	MT
Recce Pharmaceuticals Ltd Doses First Participants in Next Cohort of Phase I/II Urinary Tract Infections and Urosepsis Rapid Infusion Clinical Trial	05-17	CI
Recce Pharmaceuticals Doses First Patient in Urosepsis Rapid Infusion Clinical Trial	05-15	MT
Recce Pharmaceuticals Reports Positive Preclinical Data of Recce® 327 in Lung Infection Pilot Study	05-13	CI
Recce Pharmaceuticals Finds 'Promising' Results From Nebulized RECCE 327 Pilot Study	05-10	MT
Recce Pharmaceuticals Ltd Receives New Patent in China for RECCE Anti-Infectives from China National Intellectual Property Administration	05-08	CI
Recce Pharmaceuticals Obtains China Patent for Anti-Infectives	05-07	MT
Recce Pharmaceuticals Ltd. Announces Safety Committee Approves High Dose of 4,000mg in Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and Urosepsis	04-30	CI
Recce Pharmaceuticals Ltd. Completes 5,000 RECCE 327 Doses Week Under Good Manufacturing Practice	04-17	CI
Recce Pharmaceuticals Advances Production of Anti-Infective Medication	04-16	MT
Recce Pharmaceuticals Ltd Receives New Patent in Israel for Recce Anti-Infectives	04-04	CI
Recce Pharmaceuticals Secures Israeli Patent for Anti-Infective Medication; Shares Rise 5%	04-03	MT
Recce Pharmaceuticals Secures Canadian Trademark for Antibiotic Medications	03-21	MT
Recce Pharmaceuticals Completes Dosing Cohort in Phase I/II Trial of Recce® 327 for Urinary Tract Infections and Urosepsis	03-19	CI
Recce Pharmaceuticals Concludes Cohort Dosing in Synthetic Anti-Infectives Trial	03-15	MT
Recce Pharmaceuticals Ltd Doses Next Cohort in Phase I/II Trial of RECCE 327 for Urinary Tract Infections and Urosepsis	03-14	CI

Chart Recce Pharmaceuticals Ltd

Duration

Period

More charts

Company Profile

Recce Pharmaceuticals Ltd is an Australia-based company engaged in the development and commercialization of a new class of synthetic anti-infectives designed to address the urgent global health problems of antibiotic-resistant superbugs and emerging viral pathogens. The Company's anti-infective pipeline includes three broad-spectrum, synthetic polymer anti-infectives: RECCE 327 as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria including their superbug forms; RECCE 435 as an orally administered therapy for bacterial infections; and RECCE 529 for viral infections. Through their multi-layered mechanisms of action, the Company's anti-infectives have the potential to overcome the hypercellular mutation of bacteria and viruses. All RECCE compounds are water soluble at all pH levels in their liquid form.

Sector

Pharmaceuticals

Calendar

29/08/2024 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Recce Pharmaceuticals Ltd

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
RECCE PHARMACEUTICALS LTD	-14.02%	70.07M
ELI LILLY AND COMPANY	+56.49%	848B
NOVO NORDISK A/S	+32.66%	627B
JOHNSON & JOHNSON	-0.39%	363B
MERCK & CO., INC.	+15.80%	318B
ABBVIE INC.	+12.56%	299B
ASTRAZENECA PLC	+15.10%	243B
NOVARTIS AG	+16.96%	225B
AMGEN INC.	+16.42%	179B
PFIZER, INC.	+4.72%	167B

Other Pharmaceuticals

Recce Pharmaceuticals Ltd

Equities

RCE

AU000000RCE5

Pharmaceuticals

8,754,423 Class A Performance Shares of Recce Limited are subject to a Lock-Up Agreement Ending on 15-JAN-2018.

Latest news about Recce Pharmaceuticals Ltd

Chart Recce Pharmaceuticals Ltd

Company Profile

Income Statement Evolution

Ratings for Recce Pharmaceuticals Ltd

EPS Revisions

Annual profits - Rate of surprise

Sector Other Pharmaceuticals